Checklist
Evaluate your CGT strategy and readiness for payer engagement
Payer decision-making trends are affecting access to critical cell and gene therapies (CGTs). To help manufacturers determine their ability to respond to these trends with actionable market access strategies, we have compiled the following checklist. It’s designed to evaluate your readiness to meet payers’ needs and optimize product access during pre-approval, approval phase, and post-approval phases.
It is based on a proprietary survey of 19 payer decision-makers Cencora recently conducted to understand the challenges payers face in making CGT coverage decisions and the support manufacturers can provide to help.
For each question, simply select either yes or no based on your cell or gene therapy. Your responses will help to inform steps you can take — including value-based contracting, long-term evidence, operational clarity, and sustainable reimbursement models — to support CGT coverage and optimize market access.
It is based on a proprietary survey of 19 payer decision-makers Cencora recently conducted to understand the challenges payers face in making CGT coverage decisions and the support manufacturers can provide to help.
For each question, simply select either yes or no based on your cell or gene therapy. Your responses will help to inform steps you can take — including value-based contracting, long-term evidence, operational clarity, and sustainable reimbursement models — to support CGT coverage and optimize market access.
Pre-approval phase: Engagement with payers
Approval phase: Clear communication and sufficient evidence
Post-approval phase: Reinforce the value and optimize reimbursement
Score: 0 / 9
Scoring and results after completing the self-evaluation
0-3 points: Basic readiness
There may be significant gaps in your readiness to engage payers.
4-6 points: Intermediate readiness
You are partially successful engaging payers, but there may be areas for improvement.
7-9 points: Advanced readiness
Your payer engagement is robust, but continuous evaluation and improvement may help.
There may be significant gaps in your readiness to engage payers.
4-6 points: Intermediate readiness
You are partially successful engaging payers, but there may be areas for improvement.
7-9 points: Advanced readiness
Your payer engagement is robust, but continuous evaluation and improvement may help.
This checklist may contain marketing statements and shall not constitute legal advice. Cencora, Inc. strongly encourages readers to review all available information related to the topics mentioned herein and to rely on their own experience and expertise in making decisions related thereto.
Download the payer engagement playbook
To learn more about the steps can take to help payer with the challenges they face with CGTs and insights on how to optimize market access, see Cencora’s Cell and Gene Therapy Playbook for Payer Engagement or contact Cencora’s CGT team for customized recommendations.
